Abstract:Yang-Hua Xiao, 1, 2 Mei-Fang Liu, 1 Hongwen Wu, 1, 3 De-Rong Xu, 1 Rui Zhao 1 1 Department of Clinical Laboratory, Medical Center for Burn and Plastic Surgery, The First Affiliated Hospital of Nanchang University, Nanchang, People's Republic of China; 2 School of Public Health, Nanchang University, Nanchang, People's Republic of China; 3 Department of Medical Instruments, The First Affiliated Hospital of Nanchang University, Nanchang, People's Republic of China Correspondence: De-Rong Xu; Rui Zhao, Email ; Purpose: Metagenomic next-generation sequencing (mNGS) is a powerful yet unbiased method to identify pathogens in suspected infections. However, little is known about its clinical effectiveness. The present study aimed to assess the efficacy of mNGS in routine clinical practice. Patients and Methods: In this single-center retrospective cohort study, 518 patients with suspected infectious diseases were assessed for inclusion. Among them, each patient had undergone mNGS testing; 407 patients had undergone both microbial culture and mNGS testing. The result of mNGS testing was compared to microbial culture performed concurrently. The diagnostic performance of mNGS was evaluated using the comprehensive clinical diagnosis as the reference standard. Results: There was a significant difference in the positive detection rates of pathogens between mNGS and culture (331/407, 81.3% vs 79/407, 19.4%, P < 0.001). The sensitivity of mNGS was much higher than the culture method (79.5% vs 21.3%, P < 0.001), especially in sample types of sputum and bronchoalveolar lavage fluid (BALF). Notably, the sensitivity of blood mNGS was relatively lower than other sample types (67.4% vs 88.9– 93.8%). Pathogen cfDNA load based on standardized stringently mapped read number at the species level of microorganisms (SDSMRN) was significantly lower in blood than in other sample types from the same patient ( P = 0.0003). Importantly, mNGS directly led to a change of treatment regimen in 142 (27.4%) cases, including antibiotic escalation (15.3%), antibiotic de-escalation (9.1%), and early definitive diagnosis to initiate appropriate treatment (3.1%). Conclusion: Our in-house mNGS platform significantly improved the sensitivity for the diagnosis of infectious diseases. mNGS has the potential to improve clinical outcomes by optimizing antimicrobial therapy. Keywords: mNGS, infections, diagnostic, outcome Infections are the major cause of human deaths worldwide and present a rising threat to public security. 1 Antimicrobial resistance is a major concern that is threatening our ability to treat bacterial infections. 2 Delayed administration of antibiotics significantly increases the in-hospital mortality rate. 3 The tragic outcome of infection highlights the importance of timely diagnosis and appropriate antibiotic treatment of advanced diseases. Conventional microbiologic culture and microscopy remain the gold standard for diagnostics. Full identification of fastidious microorganisms is usually reserved for cases where an isolate is in pure culture. 4,5 However, it is a laborious and time-consuming procedure requiring several days to accomplish. Additionally, the sensitivity of the culture method depends largely on the duration of the infection and whether the patient has previously received antibiotic treatment. 6 For these reasons, rapid and accurate identification of unknown pathogenic microorganisms is critical to guide clinical decision-making about diagnosis and treatment. Molecular methods, such as polymerase chain reaction (PCR), are an alternative method when culture-based microbial detection methods fail. 7,8 However, the preselected target pathogens greatly limit the application of multiplex PCR in identifying infections caused by mixed pathogens. 9 PCR-based analyses may fail to detect unexpected, rare, or novel pathogens unless multiplexed PCRs covering all pathogenic microorganisms are employed. The clinical symptoms and etiologies of multiple infections are complex and diverse, so it is difficult to diagnose using conventional microbial methods. 10,11 This may complicate further treatment (eg, delay antimicrobial treatment, lead to antibiotics overuse, prolong hospitalizations, and increase healthcare costs). Accurate and timely diagnosis is essential for aggressive antimicrobial adjustment. These barriers are not insurmountable obstacles to treating infectious diseases. Metagenomic next-generation sequencing (mNGS) is an untargeted molecular approach that can theoretically detect all potential pathogens in a single experiment. As a -Abstract Truncated-

Comparison of clinical metagenomics with 16S rDNA Sanger sequencing for the bacteriological diagnosis of culture-negative samples

Prospective Comparison Between Shotgun Metagenomics and Sanger Sequencing of the 16S rRNA Gene for the Etiological Diagnosis of Infections

Performance of clinical metagenomics in France: a prospective observational study

Diagnostic accuracy of metagenomic next-generation sequencing in diagnosing infectious diseases: a meta-analysis

Comparison of an automated DNA extraction and 16S rDNA real time PCR/sequencing diagnostic method using optimized reagents with culture during a 15-month study using specimens from sterile body sites

16S rDNA PCR-DGGE and sequencing in the diagnosis of neonatal late-onset septicemia

Evaluation of 16S-Based Metagenomic NGS as Diagnostic Tool in Different Types of Culture-Negative Infections

Performance of 16S rRNA Gene Next-Generation Sequencing and the Culture Method in the Detection of Bacteria in Clinical Specimens

Diagnostic performance of metagenomic sequencing in patients with suspected infection: a large-scale retrospective study

Validation and Retrospective Clinical Evaluation of a Quantitative 16S rRNA Gene Metagenomic Sequencing Assay for Bacterial Pathogen Detection in Body Fluids

Microbiological Diagnostic Performance of Metagenomic Next-generation Sequencing When Applied to Clinical Practice.

The Comparison of Metagenomic Next-Generation Sequencing with Conventional Microbiological Tests for Identification of Pathogens and Antibiotic Resistance Genes in Infectious Diseases

A Retrospective Paired Comparison Between Untargeted Next Generation Sequencing and Conventional Microbiology Tests With Wisely Chosen Metagenomic Sequencing Positive Criteria

Comparison of metagenomic next-generation sequencing and blood culture in patients with suspected bloodstream infection

Comparison of 16S Ribosomal RNA Targeted Sequencing and Culture for Bacterial Identification in Normally Sterile Body Fluid Samples: Report of a 10-Year Clinical Laboratory Review

Comparison of pathogen detection consistency between metagenomic next-generation sequencing and blood culture in patients with suspected bloodstream infection

Clinical Efficacy and Diagnostic Value of Metagenomic Next-Generation Sequencing for Pathogen Detection in Patients with Suspected Infectious Diseases: A Retrospective Study from a Large Tertiary Hospital

16S metagenomics for diagnosis of bloodstream infections: opportunities and pitfalls

[Evaluation of the performance of Cepheid® GeneXpert MRSA/SA Blood Culture assay and results' extrapolation to coagulase-negative staphylococci]

Clinical application of amplification-based versus amplification-free metagenomic next-generation sequencing test in infectious diseases

Comparison of metagenomic next-generation sequencing and blood culture for diagnosis of bloodstream infections